FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
The FDA has granted priority review status for the supplemental NDA for ZERBAXA, which includes cefotolozane sulfate and tazobactam sodium.
Company
Pharmaceutical intelligence for Cubist Pharmaceuticals with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.